ライフサイエンスコーパス: aphthous

1 testinal manifestations were bloating (20%), aphthous stomatitis (18%), alternating bowel habit (15%)

2 ociated with a higher incidence of recurrent aphthous stomatitis (25% vs 11%; OR, 3.79 [95% CI, 2.67

3 mented oral manifestations such as Recurrent Aphthous Stomatitis (RAS) and Molar-Incisor Hypominerali

4 Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are common chronic inflammator

5 Recurrent aphthous stomatitis (RAS) is the most common disease aff

6 d to the clinic with complaints of recurrent aphthous stomatitis (RAS), 2 children (5% of the MIH gro

7 evaluate the use of ozone to treat recurrent aphthous stomatitis (RAS).

8 eral clinical diagnoses, including recurrent aphthous stomatitis (RAS).

9 dies revealed an increased risk of recurrent aphthous stomatitis associated with polymorphism of IL-1

10 Recurrent aphthous stomatitis can be associated with systemic dise

11 tudies reported that patients with recurrent aphthous stomatitis had a higher frequency of nutritiona

12 Associated with the fevers are aphthous stomatitis in 70% of patients, pharyngitis in 7

13 Recurrent aphthous stomatitis is characterized by symptomatic roun

14 sorders on a common spectrum, with recurrent aphthous stomatitis on the mild end, Behcet's disease on

15 cal basis of periodontal diseases, recurrent aphthous stomatitis, and candidiasis.

16 , including oral lichen planus and recurrent aphthous stomatitis, are painful and highly prevalent, y

17 ustrate genetic similarities among recurrent aphthous stomatitis, PFAPA, and Behcet's disease, placin

18 We report an adult case of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) s

19 : cyclic neutropenia and the periodic fever, aphthous stomatitis, pharyngitis, and adenopathy (PFAPA)

20 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis

21 Periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis

22 The syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis

23 riodic fever syndrome PFAPA (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis)

24 is of the pediatric disorder periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFA

25 by fever which was persist for several days, aphthous stomatitis, tongued tonsillitis with moss, phar

26 distinct from Behcet's disease and recurrent aphthous stomatitis.

27 ve disorders, Behcet's disease and recurrent aphthous stomatitis.

28 ds are first-line agents to manage recurrent aphthous stomatitis; however, systemic medications may b

29 yndrome, dermatitis herpetiformis, recurrent aphthous syndrome and enamel defects, unexplained ataxia

30 11%] patients), headache (19 [9%] patients), aphthous ulcer (15 [7%] patients), and nausea (13 [6%] p

31 atients had adverse events in the extension (aphthous ulcer).

32 study: hepatic enzyme increased, dizziness, aphthous ulcer, arthralgia, arthritis, increased appetit

33 Recurrent aphthous ulceration (RAU) is characterized by an ulcerat

34 6% of the patients had experienced recurrent aphthous ulceration and GFD brought relief to 69% of the

35 , including dental enamel defects, recurrent aphthous ulceration and glossodynia.

36 icacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immun

37 Thalidomide is effective in healing aphthous ulceration of the esophagus in patients infecte

38 HIV-infected patients with biopsy-confirmed aphthous ulceration of the esophagus were randomly assig

39 uman immunodeficiency virus (HIV) infection, aphthous ulceration of the mouth and oropharynx can beco

40 Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patie

41 patients had higher prevalence of recurrent aphthous ulceration than did the controls (17% vs. 13%,

42 Ileocolonoscopy findings of extensive aphthous ulceration with skip lesions extending to the t

43 Most common toxicity was mild aphthous ulceration.

44 was shown beneficial in relieving recurrent aphthous ulcerations in patients with coeliac disease.

45 300 mg and 150 mg doses, respectively), and aphthous ulcers (38 [4%] of 870 and six [3%] of 214, res

46 p (55 percent) had complete healing of their aphthous ulcers after four weeks, as compared with only

47 peutic presently used in the clinic to treat aphthous ulcers and asthma, is an inhibitor of these kin

48 Saliva from patients with aphthous ulcers and Behcet disease prone to oral ulcers

49 o of the more common oral mucosal disorders: aphthous ulcers and recurrent herpes simplex labialis.

50 virus (HIV)-associated conditions, including aphthous ulcers and wasting syndrome.

51 Dry mouth, oral candidiasis, and recurrent aphthous ulcers are 3 of the most common oral conditions

52 Dry mouth, oral candidiasis, and recurrent aphthous ulcers are common oral conditions that may be a

53 receive thalidomide had complete healing of aphthous ulcers at the 4-week endoscopic evaluation, com

54 led study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients.

55 s is ineffective at preventing recurrence of aphthous ulcers in HIV-infected persons.

56 reventing recurrences of oral and esophageal aphthous ulcers in patients with human immunodeficiency

57 The hypothesis tested was that aphthous ulcers may lack key extracellular matrix compon

58 In general, peripheral arthritis, oral aphthous ulcers, episcleritis, or erythema nodosum can b

59 not in pseudohairy leukoplakia lesions, oral aphthous ulcers, or oral KS lesions.

60 ver time, but no change in the occurrence of aphthous ulcers.

61 thalidomide may promote the healing of oral aphthous ulcers.

62 candidiasis, and topical corticosteroids for aphthous ulcers.